These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 6592942)

  • 41. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
    Hermosillo AJ; Spinler SA
    Ann Pharmacother; 2008 Jun; 42(6):790-805. PubMed ID: 18477734
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes.
    Testa L; Zoccai GB; Porto I; Trotta G; Agostoni P; Andreotti F; Crea F
    Am J Cardiol; 2007 Jun; 99(12):1637-42. PubMed ID: 17560866
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ticlopidine: a second look. No further use in routine practice.
    Prescrire Int; 1999 Oct; 8(43):142-4. PubMed ID: 11503839
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Stent after-care: new approaches to coagulation inhibiting therapy].
    Mudra H
    Herz; 1995 Jun; 20(3):221-3. PubMed ID: 7635403
    [No Abstract]   [Full Text] [Related]  

  • 45. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding.
    Khurram Z; Chou E; Minutello R; Bergman G; Parikh M; Naidu S; Wong SC; Hong MK
    J Invasive Cardiol; 2006 Apr; 18(4):162-4. PubMed ID: 16729401
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of ticlopidine and aspirin on endotoxin-induced disseminated intravascular coagulation in rats.
    Paris J
    Thromb Haemost; 1983 Dec; 50(4):894-5. PubMed ID: 6665770
    [No Abstract]   [Full Text] [Related]  

  • 47. [Ticlopidine-induced lymphocytic colitis].
    Rosa I; Nahon S; Cohen C; Abd Alsamad I; Fléjou JF; Hagege H; Chousterman M
    Ann Med Interne (Paris); 1999 Sep; 150(5):437-9. PubMed ID: 10544755
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effect of ticlopidine in the prevention of recurrences of cerebral ischemic accidents: comparative study with dipyridamol].
    Sancho Rieger J; López-Trigo Picho J
    Med Clin (Barc); 1984 Jan; 82(2):62-4. PubMed ID: 6608645
    [No Abstract]   [Full Text] [Related]  

  • 49. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
    Jernberg T; Payne CD; Winters KJ; Darstein C; Brandt JT; Jakubowski JA; Naganuma H; Siegbahn A; Wallentin L
    Eur Heart J; 2006 May; 27(10):1166-73. PubMed ID: 16621870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
    Jakubowski JA; Payne CD; Weerakkody GJ; Brandt JT; Farid NA; Li YG; Naganuma H; Lachno DR; Winters KJ
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):167-73. PubMed ID: 17414229
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Severe neutropenia caused by ticlopidine].
    Martín Casellas E; Bosch Llobet A; Tous Quintana R
    Med Clin (Barc); 1991 Jun; 97(2):76. PubMed ID: 1895788
    [No Abstract]   [Full Text] [Related]  

  • 52. Digital era drug surveillance: Quo vadis, Australia?
    Raubenheimer JE; Barratt MJ
    Drug Alcohol Rev; 2018 Sep; 37(6):693-696. PubMed ID: 30175478
    [No Abstract]   [Full Text] [Related]  

  • 53. [Severe chronic diarrhea during treatment with ticlopidine].
    Chassany O; Bacq Y; Metman EH; Gillion JM; Dorval ED; Jankowski JM
    Gastroenterol Clin Biol; 1989 Nov; 13(11):950. PubMed ID: 2612838
    [No Abstract]   [Full Text] [Related]  

  • 54. Quo vadis, aspirin?
    Capodanno D
    EuroIntervention; 2018 Dec; 14(11):e1153-e1157. PubMed ID: 30522983
    [No Abstract]   [Full Text] [Related]  

  • 55. Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states.
    Saltiel E; Ward A
    Drugs; 1987 Aug; 34(2):222-62. PubMed ID: 3304967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ticlopidine: quo vadis? Adverse reactions in man.
    Goyan JE
    Agents Actions Suppl; 1984; 15():116-25. PubMed ID: 6592942
    [No Abstract]   [Full Text] [Related]  

  • 57. Ticlopidine: quo vadis? Subarachnoid hemorrhage.
    Ono H; Mizukami M; Kitamura K; Kikuchi H
    Agents Actions Suppl; 1984; 15():259-72. PubMed ID: 6385650
    [No Abstract]   [Full Text] [Related]  

  • 58. Leukopenia due to ticlopidine in a patient with chronic renal failure.
    Bedani PL; Fiocchi O; Scapoli PL; Farinelli A
    Haematologica; 1984; 69(5):641-2. PubMed ID: 6437940
    [No Abstract]   [Full Text] [Related]  

  • 59. Adverse reactions to anticoagulants and to antiplatelet drugs recorded by the German spontaneous reporting system.
    Tiaden JD; Wenzel E; Berthold HK; Müller-Oerlinghausen B
    Semin Thromb Hemost; 2005; 31(4):371-80. PubMed ID: 16149013
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overview: clinical experiences with ticlopidine.
    Day HJ
    Agents Actions Suppl; 1984; 15():297-309. PubMed ID: 6385654
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.